Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial.
暂无分享，去创建一个
A. Schuh | D. Cairns | J. Shingles | S. Paneesha | F. Forconi | A. Rawstron | D. Allsup | Sharon M Jackson | T. Munir | P. Hillmen | C. Fox | B. Kennedy | K. Cwynarski | A. Broom | P. Patten | R. Walewska | M. Furtado | A. Hockaday | G. Sidra | A. Bloor | D. Howard | J. Neilson | S. Dalal | N. Webster | G. Preston | N. Elmusharaf | N. Pemberton | A. Pitchford | Moya Young | N. Greatorex | Julia M Brown | N. Morley | Julia M. Brown | Talha Munir | Nagah Elmusharaf